Literature DB >> 10927135

Combined chemoradiotherapy with daily low-dose cisplatin in locally advanced inoperable non-small cell lung cancer.

B Biedermann1, C Landmann, R Kann, J Passweg, M Solèr, A Lohri, C Rochlitz, R Herrmann, M Pless.   

Abstract

Sixty-one consecutive patients with locally advanced inoperable non-small-cell lung cancer were treated with chemoradiation with 60 Gy and concomitant daily low-dose cisplatin (6 mg/m(2)) in a single uninterrupted course. Toxicity was mild, 80% of patients were treated as outpatients. The median survival of 70 weeks compares favorably to the literature.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10927135     DOI： 10.1016/s0167-8140(00)00203-6

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN： 0167-8140            Impact factor:   6.280


  2 in total

1.  Cisplatin Every 3 Weeks Versus Weekly With Definitive Concurrent Radiotherapy for Squamous Cell Carcinoma of the Head and Neck.

Authors:  Joshua M Bauml; Ravi Vinnakota; Yeun-Hee Anna Park; Susan E Bates; Tito Fojo; Charu Aggarwal; Sewanti Limaye; Nevena Damjanov; Jessica Di Stefano; Christine Ciunci; Eric M Genden; Juan P Wisnivesky; Rocco Ferrandino; Ronac Mamtani; Corey J Langer; Roger B Cohen; Keith Sigel
Journal:  J Natl Cancer Inst       Date:  2019-05-01       Impact factor: 13.506

2.  Comparison of Myelotoxicity and Nephrotoxicity Between Daily Low-Dose Cisplatin With Concurrent Radiation and Cyclic High-Dose Cisplatin in Non-Small Cell Lung Cancer Patients.

Authors:  Zulfan Zazuli; Renate Kos; Joris D Veltman; Wilma Uyterlinde; Cristina Longo; Paul Baas; Rosalinde Masereeuw; Susanne J H Vijverberg; Anke-Hilse Maitland-van der Zee
Journal:  Front Pharmacol       Date:  2020-06-26       Impact factor: 5.810
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.